Publications by authors named "Michael Olin"

Claim this Profile
T
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors.
Stephen C Frederico, Itay Raphael, Michal Nisnboym, Sakibul Huq, Brent T Schlegel, Michael R Olin

Expert Rev Clin Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection.
Itay Raphael, Anzar A Mujeeb, Elisabet Ampudia-Mesias, ReidAnn E Sever, Brandon McClellan, Michael R Olin

bioRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
Mason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Michael Olin

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma vaccines: past, present, and opportunities.
Zujian Xiong, Itay Raphael, Michael Olin, Hideho Okada, Xuejun Li

EBioMedicine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma.
Lindsey Greenlund, Ryan Shanley, Kellen Mulford, Elizabeth C Neil, Jessica Lawrence, Michael Olin

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and characterization of two novel patient-derived lines from canine high-grade glioma.
Morgan S Schrock, Abigail A Zalenski, Miranda M Tallman, Luke Kollin, Anna Bratasz, Michael R Olin

Vet Comp Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.
Mason J Webb, Timothy Kottke, Benjamin L Kendall, Jack Swanson, Chisom Uzendu, Michael Olin

Mol Ther Oncolytics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors.
Christopher Moertel, Francisco Martinez-Puerta, Grace G Elizabeth Pluhar, Maria Graciela Castro, Michael Olin

Expert Opin Investig Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Mahmoud S Alghamri, Kaushik Banerjee, Anzar A Mujeeb, Ava Mauser, Ayman Taher, Michael R Olin

ACS Nano· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
Hirokazu Ogino, Jennie W Taylor, Takahide Nejo, David Gibson, Payal B Watchmaker, Michael R Olin, Annette M Molinaro

J Clin Invest· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.
Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, David Zellmer, Andrew Janeiro, Michael R Olin

Neurotherapeutics· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.
Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, David Zellmer, Andrew Janeiro, Michael R Olin

Neurotherapeutics· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.
Mahmoud S Alghamri, Brandon L McClellan, Carson S Hartlage, Santiago Haase, Syed Mohd Faisal, Michael R Olin

Front Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
Zhengming Xiong, Elisabet Ampudia Mesias, G Elizabeth Pluhar, Susan K Rathe, David A Largaespada, Michael R Olin

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma.
Michael R Olin, Elisabet Ampudia-Mesias, Christopher A Pennell, Aaron Sarver, Clark C Chen

Cancers (Basel)· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-derived exosomes, microRNAs, and cancer immune suppression.
Michael W Graner, Sathya Schnell, Michael R Olin

Semin Immunopathol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
Peter Larson, Tamara A Kucaba, Zhengming Xiong, Michael Olin, Thomas S Griffith

ACS Med Chem Lett· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
Zhengming Xiong, Elisabet Ampudia-Mesias, Rob Shaver, Craig M Horbinski, Christopher L Moertel, Michael R Olin

Immunotherapy· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.
G Elizabeth Pluhar, Christopher A Pennell, Michael R Olin

Crit Rev Immunol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant.
Brian M Andersen, Junzhe Xia, Alan L Epstein, John R Ohlfest, Wei Chen, Michael R Olin

J Immunother Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.
Michael R Olin, G Elizabeth Pluhar, Brian M Andersen, Rob Shaver, Nate N Waldron

Crit Rev Immunol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
Christopher L Moertel, Junzhe Xia, Rebecca LaRue, Nate N Waldron, Brian M Andersen, Michael R Olin

J Immunother Cancer· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.
Michael R Olin, Walter Low, David H McKenna, Stephen J Haines, Tambra Dahlheimer

J Immunother Cancer· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
Charles E Schiaffo, Ce Shi, Zhengming Xiong, Michael Olin, John R Ohlfest

J Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of a novel scFv recognizing human and mouse CD133.
Suresh Kumar Swaminathan, Lin Niu, Nate Waldron, Steve Kalscheuer, David M Zellmer, Michael R Olin

Drug Deliv Transl Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis